Business Wire

Adtran launches Oscilloquartz SFP grandmaster clock for precise edge timing in 10G networks

9.9.2025 14:00:00 CEST | Business Wire | Press release

Share

News summary: OSA 5401XG SyncPlug™ delivers PTP and NTP synchronization from a compact, plug-in device designed for 10G infrastructure New SFP timing solution combines multi-band GNSS, spoofing resilience, PRTC‑B compliance and support for regional navigation systems Compact, efficient design brings synchronization to space-constrained environments across telecom, energy, defense, enterprise and more

Adtran today launched the OSA 5401XG SyncPlug™, an SFP-based grandmaster clock that delivers precise PTP and NTP synchronization for 10Gbit/s edge and access networks. The new Oscilloquartz device enables timing distribution through a compact, plug-in form factor that requires no rack space or complex installation, empowering network operators to extend synchronization into space- and power-limited deployments. With multi-band GNSS support, compliance with PRTC‑B and compatibility with 10Gbit/s-only host platforms, it offers an efficient way to upgrade timing capabilities across sectors, including telecom, energy, defense, enterprise and more.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250909324407/en/

Adtran’s new OSA 5401XG SyncPlug™ integrates seamlessly into existing infrastructure, delivering precise synchronization wherever it’s needed.

“As networks evolve, precise timing has to reach further, faster and into more constrained environments. That’s exactly what the 5401XG SyncPlug is built for. It’s a no-compromise solution that fits directly into existing infrastructure, requires almost no space or power and delivers the performance needed for next-generation services,” said Gil Biran, GM of Oscilloquartz, Adtran. “By integrating advanced GNSS capabilities in a 10Gbit/s-ready SFP module, we’re giving our customers an easier, smarter way to deploy resilient timing, whether modernizing legacy sites, extending coverage at the edge or rolling out new, timing-critical applications.”

The OSA 5401XG SyncPlug is a fully featured SFP-based synchronization device that supports PTP grandmaster, boundary and slave clock modes, Stratum 1 NTP server functionality, and SyncE for frequency synchronization. It plugs directly into standard 1Gbit/s or 10Gbit/s ports and consumes less than 2.5W, making it ideal for space- and power-sensitive locations. With multi-band GNSS (L1 and L5), the device enables compliance with enhanced timing standards such as PRTC-B and supports regional systems, including India’s IRNSS. It also offers advanced spoofing and jamming detection, extended holdover and up to 500,000 NTP transactions per second, ensuring performance and security at scale.

“Demand for precise synchronization is growing rapidly across edge and access networks, and it has to be delivered with minimal footprint and maximum resilience,” commented Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “From mobile backhaul and energy grids to secure government and business networks, the OSA 5401XG SyncPlug fits directly into existing infrastructure to deliver full grandmaster functionality over 10Gbit/s. There’s no need for extra cabling, appliances or rack space. It’s an ideal solution for operators looking to modernize timing in challenging environments while simplifying deployment and strengthening performance.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the majority shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250909324407/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye